| Autor: |
Brown KL; Microbiology and Immunology, The Life Sciences Institute, The University of British Columbia, Vancouver, Canada., Wilburn KM; Microbiology and Immunology, Cornell University, Ithaca, New York, USA., Montague CR; Microbiology and Immunology, Cornell University, Ithaca, New York, USA., Grigg JC; Microbiology and Immunology, The Life Sciences Institute, The University of British Columbia, Vancouver, Canada., Sanz O; Diseases of the Developing World, GlaxoSmithKline R1D, Ltd., Tres Cantos, Madrid, Spain., Pérez-Herrán E; Diseases of the Developing World, GlaxoSmithKline R1D, Ltd., Tres Cantos, Madrid, Spain., Barros D; Diseases of the Developing World, GlaxoSmithKline R1D, Ltd., Tres Cantos, Madrid, Spain., Ballell L; Diseases of the Developing World, GlaxoSmithKline R1D, Ltd., Tres Cantos, Madrid, Spain., VanderVen BC; Microbiology and Immunology, Cornell University, Ithaca, New York, USA., Eltis LD; Microbiology and Immunology, The Life Sciences Institute, The University of British Columbia, Vancouver, Canada. |
| Abstrakt: |
Despite the deployment of combination tuberculosis (TB) chemotherapy, efforts to identify shorter, nonrelapsing treatments have resulted in limited success. Recent evidence indicates that GSK2556286 (GSK286), which acts via Rv1625c, a membrane-bound adenylyl cyclase in Mycobacterium tuberculosis, shortens treatment in rodents relative to standard of care drugs. Moreover, GSK286 can replace linezolid in the three-drug, Nix-TB regimen. Given its therapeutic potential, we sought to better understand the mechanism of action of GSK286. The compound blocked growth of M. tuberculosis in cholesterol media and increased intracellular cAMP levels ~50-fold. GSK286 did not inhibit growth of an rv1625c transposon mutant in cholesterol media and did not induce cyclic AMP (cAMP) production in this mutant, suggesting that the compound acts on this adenylyl cyclase. GSK286 also induced cAMP production in Rhodococcus jostii RHA1, a cholesterol-catabolizing actinobacterium, when Rv1625c was heterologously expressed. However, these elevated levels of cAMP did not inhibit growth of R. jostii RHA1 in cholesterol medium. Mutations in rv1625c conferred cross-resistance to GSK286 and the known Rv1625c agonist, mCLB073. Metabolic profiling of M. tuberculosis cells revealed that elevated cAMP levels, induced using either an agonist or a genetic tool, did not significantly affect pools of steroid metabolites in cholesterol-incubated cells. Finally, the inhibitory effect of agonists was not dependent on the N -acetyltransferase MtPat. Together, these data establish that GSK286 is an Rv1625c agonist and sheds light on how cAMP signaling can be manipulated as a novel antibiotic strategy to shorten TB treatments. Nevertheless, the detailed mechanism of action of these compounds remains to be elucidated. |
